Key facts
- It has raised $56.7M; the latest was Later Stage VC in Jul 2024.
- Notable investors include Verve Ventures, Zürcher Kantonalbank, SambrInvest, Federal Holding and Investment Company (Brussels), Société Régionale d'Investissement de Wallonie — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for OncoDNA
- ·The full record, as it builds
Funding rounds
No funding rounds for OncoDNA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About OncoDNA
Operator of a theranostic and genomic company intended to provide precision medicine to treat cancer and genetic diseases. The company provides clinical guidance for the treatment and real-time monitoring of late-stage cancer patients and also supports research and drug development in cancer and genetic diseases, helping clinicians, academic researchers, and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine.
- Sector
- Healthcare
- HQ
- Gosselies, Belgium
- Founded
- 2012
- Employees
- 100
- Website
- oncodna.com/
- Ownership
- Privately Held (backing)
OncoDNA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OncoDNA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OncoDNA in its N-PORT filings yet. We sweep new filings monthly.